The use of Posaconazole, also known as the brand name Noxafil, continues to be a reliable and effectual therapy for fighting fungal infections. Posaconazole is FDA approved to treat fungal infections occurring in patients with weakened immune systems, like patients with HIV infection or those who are recovering from stem cell transplantation. In March 2014,[…]
Posaconazole as a Reliable Antifungal Therapy
Anti-Fungal Tags: acute myeloid leukemiaHIV infection Oct 20, 2015
Pyrazinamide is a Triple Threat to TB in HIV Patients
Anti-Retroviral / Anti-HIV, Antibacterial, Antibiotic, Drug Research & Development API Tags: HIV infectionHIV virus Aug 08, 2014
Midstage trial data of a Pyrazinamide cocktail to treat TB has offered encouraging news for patients with the HIV infection. Coined PaMZ, this drug trio includes Pyrazinamide and two antibacterial drugs, with results going into the Phase III trial looking promising. The antibacterial drugs are PA-824, which was initially developed by the Novartis and the[…]
Dolutegravir Approved by the FDA as an Effectual Integrase Inhibitor
Anti-Retroviral / Anti-HIV Tags: AIDSHIV infectionHIV virus Aug 26, 2013
On August 12, 2013 Viiv Healthcare proudly announced the FDA approval of the integrase inhibitor, Dolutegravir to combat the HIV virus. Known as the brand name Tivicay, Dolutegravir is typically used in combination with other antiretroviral medications to treat patients with AIDS, ages twelve and older. With many patients living longer while being infected with[…]
Tenofovir Offers Significant Risk Reduction for Contracting the HIV Virus
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API, Patent Expiration 2018 Tags: HIV infection Jul 31, 2013
Breaking news in the pharmaceutical world made headlines on June 12, 2013, when the Centers for Disease Control and Prevention revealed a study touting the prophylactic benefit of Tenofovir. Coined pre-exposure prophylaxis or PrEP, this study advocating the use of Tenofovir as an interventional pre-treatment was published in the Lancet in mid- June of 2013.[…]
New Tenofovir Pro-Drug Offers Less Toxicity
Anti-Retroviral / Anti-HIV, Drug Research & Development API, Patent Expiration 2017 Tags: HIVHIV infectionHIV virus Mar 25, 2013
On March 6, 2013 The Physician’s Weekly reported that a new Tenofovir Pro-Drug had less potential for bone and kidney toxicity, but still remained efficacious as a treatment for both Hepatitis and HIV infection. The findings were revealed at the 20th Conference on Retroviruses and Opportunistic Infections 2013 in Atlanta, Georgia. Tenofovir is a vastly[…]
Rilpivirine Proves to be a Worthy HIV Opponent
Anti-Retroviral / Anti-HIV, Antiviral, FDA Approved 2011 Tags: EUHIV infectionvitamin D Nov 28, 2012
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor {NTRI} known as the brand name Edurant. Rilpivirine is used to treat HIV-1 infection, and it is often dispensed alongside other antiretroviral agents. As a 25 milligram tablet designed to be taken once daily with food, rilpivirine is effective at decreasing the amount of HIV infection in the[…]
Life Extending Enfuvirtide Looks to Become a Successful Generic
Anti-Retroviral / Anti-HIV, Patent Expiration 2013, Patent Expiration 2015 Tags: AIDSHIVHIV infectionRitonavir Jun 27, 2012
In June of 1981 the first known cases of AIDS in the United States were reported. Currently there are over 1.7 million people in the United States infected with HIV-1, the virus which causes AIDS, and over more then 600,000 Americans have already died from this ultimately fatal disease. With 1.2 million Americans estimated to[…]
Ritonavir Boosts the Efficacy of Protease Inhibitors
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: HIV infectionNorvirRitonavir May 18, 2012
Ritonavir is also known by it’s brand name Norvir. Marketed by Abbott Laboratories, Norvir will lose it’s patent on January 28, 2014. The patent for the pediatric exclusivity for ritonavir will also expire on July 28, 2014. With the generic possibilities coming near, researchers are clamoring to commence clinical trials of ritonavir. As an antiviral[…]
Darunavir Ethanolate continues to Prove it's Viability for HIV Treatment
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API Tags: antiretroviralDarunavir EthanolateHIV infectionRitonavir Apr 23, 2012
Darunavir Ethanolate is also known by it’s brand name Prezista, and is used to treat HIV infection. In the class of protease inhibitors, darunavir ethanolate was approved by the FDA in June of 2006. What makes darunavir ethanolate unique is it’s ability to combat drug resistant strains of HIV in affected patients, as well as[…]
